- taking tocilizumab or hydroxychloroquine deferoxamine within one month prior to inclusion (excluding participation in thinc or covid_2pro or covid+pa studies) - severe/severe liver failure - dialysis patients - renal insufficiency (clearance< 30ml/min/1.73m2) - allergy to deferoxamine - pregnant or breastfeeding woman - hypersensitivity to the active substance or any of the excipients of tocilizumab - a decrease in blood platelets with previous use of enoxaparin or another heparin drug, - hemophilia and related diseases, - stomach or duodenal ulcer

- taking tocilizumab or hydroxychloroquine deferoxamine within one month prior to inclusion (excluding participation in thinc or covid_2pro or covid+pa studies) - severe/severe liver failure - dialysis patients - renal insufficiency (clearance< 30ml/min/1.73m2) - allergy to deferoxamine - pregnant or breastfeeding woman - hypersensitivity to the active substance or any of the excipients of tocilizumab - a decrease in blood platelets with previous use of enoxaparin or another heparin drug, - hemophilia and related diseases, - stomach or duodenal ulcer